This, from the CCJ 2023 earnings call today (https://seekingalpha.com/article/4668643-cameco-corporation-ccj-q4-2023-earnings-call-transcript):We also have a 49% interest in global laser enrichment, which holds the exclusive license to deploy a third-generation uranium enrichment technology. Subject to its continued progress towards commercialization, if successful, GLE could have the ability to help meet the evolving enrichment needs of the industry, from re-enriching depleted uranium tails to producing commercial low-enriched uranium, for the global reactor fleet in operation today.To delivery of high-assay, low-enriched uranium for the SMRs and advanced reactors of tomorrow, GLE represents a significant opportunity for Cameco, to participate in every stage of the fuel cycle. We're also excited to have added a 49% share of Westinghouse to our portfolio of investments in 2023.Westinghouse is a well-established and critical business to the nuclear power industry, which gives us more exposure to the light water side of the nuclear fuel cycle, while adding potential growth opportunities related, to their conventional and advanced reactor sales. We expect our share of adjusted EBITDA from Westinghouse in 2024, to be between $445 million and $510 million.And we believe the business is well-positioned for long-term growth, driven by the expected increase in global demand for nuclear power. Over the next five years, we expect Westinghouse's adjusted EBITDA, to grow at a compound annual growth rate of 6% to 10%. But even with the significant acquisition in Westinghouse, we have maintained the capacity for further investments, should value-adding opportunities emerge.
- Forums
- ASX - By Stock
- SLX
- Cameco
SLX
silex systems limited
Add to My Watchlist
2.25%
!
$4.34

Cameco, page-51
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$4.34 |
Change
-0.100(2.25%) |
Mkt cap ! $1.033B |
Open | High | Low | Value | Volume |
$4.54 | $4.61 | $4.32 | $3.963M | 895.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 16533 | $4.31 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.39 | 3059 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 16533 | 4.310 |
1 | 2000 | 4.300 |
1 | 3059 | 4.290 |
1 | 3059 | 4.280 |
2 | 3397 | 4.260 |
Price($) | Vol. | No. |
---|---|---|
4.390 | 3059 | 1 |
4.410 | 31403 | 2 |
4.420 | 3059 | 1 |
4.440 | 3099 | 2 |
4.520 | 571 | 1 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
SLX (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online